BioTuesdays

Tag - ABOS

Acumen

Stifel starts Acumen Pharma at buy; PT $27

Stifel launched coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $27 price target. The stock closed at $17.08 on July 23. Acumen is a biotechnology company focused on the development of a next...